Cardio-Renal Syndrome, Coronary Angiography, Coronary Artery Disease, Kidney Diseases, Metabolic Syndrome
Conditions
Keywords
contrast-induced acute kidney injury, contrast medium, creatinine clearance, coronary angiography, chronic kidney disease, Adverse Cardiovascular and Kidney Events
Brief summary
As a single center, retrospective observation study in Guangdong Institute of Cardiovascular Diseases, this study included the main study population of patients who underwent coronary angiography and / or coronary intervention from January 2007 to Decemeber 2018. The hospitalization information was collected in the form of direct derivation of the case, and cardiac and renal adverse events were collected through outpatient recorder system. All-cause death information was obtained from the Public Security and matched to the electronic Clinical Management System of the Guangdong Provincial People's Hospital records.
Detailed description
This is a single center, retrospective observation study collecting data on 88938 coronary angiography and / or coronary intervention patients from January 2007 to Decemeber 2018. Data regarding demographic information, admission diagnoses and history of present illness, biomarkers and details on preventive hydration and medications will be collected. The primary endpoint of this study is All-cause mortality, and secondary endpoints are Adverse Cardiovascular and Kidney Events.
Interventions
None listed
Sponsors
Guangdong Provincial People's Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1\. Patients referred to CAG or PCI;
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-cause mortality | From hospital admission to 13 years follow-up | Admission Patients Died for all-cause mortality within 13 years. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cystatin C based CI-AKI (CI-AKI cyc) | 24-48 hours | Cystatin C based CI-AKI, defined as a ≥10% absolute increase in serum cystatin C during the first 24 hours after the procedure and and a ≥ 0.3 mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure.mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure |
| The change of eGFR, calculate based on CrCl and serum cystatin C | 48-72 hours | The eGFR creatinine-cystatin C was calculated by the 2012 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin C equation: 135 \*min(Scr/κ, 1)α \* max(Scr/κ, 1)-0.601 \* min(Scys/0.8, 1)-0.375 \* max (Scys/0.8, 1)-0.711 \* 0.995Age \[\* 0.969 if female\] \[\* 1.08 if black\], where Scr is serum creatinine, Scys is serum cystatin C, κ is 0.7 for females and 0.9 for males, α is -0.248 for females and -0.207 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. |
| Contrast-Induced Acute Kidney Injury (CI-AKI 0.3) | 48 hours | defined as a ≥ 0.3 mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure |
| Incidence of major adverse cardiovascular events | 3-12months | all-cause mortality (cardiovascular and noncardiovascular) and cardiovascular events. |
| Follow-up major adverse cardiovascular and clinical events | 3-12months | We will follow up the patients by telephone and outpatient service to know the one year all-cause mortality (cardiovascular and noncardiovascular) and cardiovascular events. |
| Contrast-induced Persistent kidney injury (CI-PKI) | 3 months | Serum creatinine was measured by endpoint colorimetry or enzymatic assays. CI-PKI was defined as residual impairment of renal function indicated by a ≥ 25% reduction in creatinine clearance at 3 months in comparison with baseline. comparison with baseline |
Countries
China
Outcome results
None listed